Rituximab Biosimilar

BIOLOGICAL6 trials

Conditions

Diffuse Large B-Cell LymphomaLymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, Large B-Cell, Diffuse (DLBCL)Nephrotic Syndrome Steroid-Dependent

Phase 2

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

NCT04246359

Huiqiang HuangLymphoma, B-Cell

Start: 2020-01-15End: 2023-01-16Target: 52Updated: 2022-04-07

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

TerminatedNCT04402580

Istituto Giannina GasliniNephrotic Syndrome Steroid-Dependent

Start: 2019-07-01End: 2020-08-31Updated: 2020-09-14

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

NCT04585152

Istituto Giannina GasliniNephrotic Syndrome Steroid-Dependent

Start: 2020-10-15End: 2023-09-30Target: 160Updated: 2022-12-21

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active, not recruitingNCT05406401

Merck Sharp & Dohme LLCLymphoma, Large B-Cell, Diffuse (DLBCL)

Start: 2022-07-14End: 2029-04-26Target: 60Updated: 2024-10-15

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

RecruitingNCT06890884

Merck Sharp & Dohme LLCLymphoma, Large B-Cell, Diffuse

Start: 2025-04-11End: 2032-12-16Target: 594Updated: 2026-04-02

Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

RecruitingNCT06717347

Merck Sharp & Dohme LLCDiffuse Large B-Cell Lymphoma

Start: 2025-01-27End: 2032-03-29Target: 1046Updated: 2026-03-27

Blood2025-11-03

Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study

Blood2025-11-03

Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study

Blood2025-11-03

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Blood2025-11-03

waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma.

Journal of Clinical Oncology2025-05-281 citations

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood2024-11-052 citations

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Blood2023-11-02

waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).

Journal of Clinical Oncology2023-06-011 citations

Blood2021-11-05

Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol

BMJ Open2021-11-0110 citations

Rituximab Biosimilar

Sponsors

Conditions

Phase 2

Phase 3

Related Papers